

CURRICULUM VITAE

NAME: Charles Frank CRADDOCK CBE
HOME ADDRESS: 4 Chantry Road, Moseley, Birmingham, B13 8DW
PLACE AND DATE OF BIRTH: London, UK
20th September, 1957
MARITAL STATUS: Married
NATIONALITY: British

EDUCATION:

1969 - 1976 Dr. Challoner's Grammar School, Amersham, Bucks
1976 - 1979 Lincoln College, Oxford University
1979 - 1982 John Radcliffe Medical School, Oxford University, Oxford

QUALIFICATIONS:

1979 BA Physiological Sciences
1982 BM BCh (Oxford)
1985 MRCP (UK)
1993 Dip RCPATH
1994 D.Phil University of Oxford
1997 MRCPATH

GMC NUMBER: 2605005

PRESENT POST:

July 2004 - present

**Professor of Haemato-oncology, University of Birmingham,
Academic Director, Centre for Clinical Haematology, Queen
Elizabeth Hospital, Birmingham**

Current post includes consultant responsibility for in-patient and out-patient care of patients on the bone marrow transplant and leukaemia units. In the past five years the UHBT stem cell transplant programme has doubled in size and is now one of the largest in the country. I am actively involved in the development of conditioning regimens and strategies aimed at augmenting immune reconstitution after allogeneic transplantation and in the development of novel therapies in acute and chronic myeloid leukaemia. In addition as Director of the Centre for Clinical Haematology I lead an active haemato-oncology clinical trials unit.

PREVIOUS POSTS:

Aug 1982 - Feb 1983

**House Physician to Professor Weatherall and Dr. Ledingham,
John Radcliffe Hospital, Oxford.**

Three months on Professor Weatherall's firm with experience in general haematology including management of acute general leukaemia, sickle cell anemia and bone marrow transplantation.

Three months on Dr. Ledingham's firm with an interest in hypertension and nephrology.

Feb 1983 - Aug 1983

**House Surgeon to Mr. P.W. Davies, Barnet General Hospital,
Barnet, London.**

Aug 1983 - Feb 1984

**Senior House Officer, Department of Cardiology, Hammersmith
Hospital, London.**

Three months with Dr. Oakley with a wide experience of general cardiology and a special interest in infective endocarditis.

Three months with Professor Maseri on the coronary care unit. Both attachments provided experience in the care of acutely ill patients. Practical procedures included central venous line.

Feb 1984 - Aug 1984

Senior House Officer, University Department of Neurology, Radcliffe Infirmary, Oxford.

Six months working for Professor Matthews, Dr. Davis, Dr. Greenhall and Dr. Warlow in a busy neurological centre with many acute admissions, including three months with responsibility for the neurological intensive therapy unit.

Aug 1984 - July 1985

Senior House Officer, Department of General Medicine, Nottingham City Hospital.

Three months experience with Professor Tattersfield and Dr. Long in chest medicine and gastroenterology. Six months working for Dr. Morgan and Dr. Burden on the renal unit with experience in acute and chronic renal failure, peritoneal and haemodialysis and renal transplantation. Three months in Newark General Hospital as Casualty and General Medical Officer.

Medical emergency admissions totalled approximately 30 per week from all of Nottingham and surrounding area. Two to three outpatient sessions attended per week. Experience gained in central venous cannulation, transvenous pacing wire and haemodialysis catheter insertion, pleural and liver biopsy.

Aug 1985 - Feb 1986

Honorary NHS Registrar, General Medicine (Infectious Disease), Nottingham City Hospital.

Six months working for Dr Finch on an infectious disease unit. Wide experience gained in both general medicine and infectious disease. Research interests centred on studying role of bacterial adherence in peritonitis in chronic ambulatory peritoneal dialysis and studying pharmacokinetics of thienamycin and ciprofloxacin.

Mar 1986 - Feb 1987

Registrar in General Medicine, Osler Chest Unit, Churchill Hospital, Oxford.

One year working for Dr Lane, Dr. Benson and Dr. Hopkin on a regional chest unit. Wide experience gained in chest medicine with clinical responsibility for two wards. Three outpatient clinics attended per week including one peripheral clinic. Experience gained in bronchoscopy and investigation of pulmonary infection in the immunocompromised host.

Feb 1987 - Aug 1987

Registrar in General Medicine, John Radcliffe Hospital, Oxford.

Six months on Professor Sleight's firm including busy general medical takes and a large cardiological workload.

Aug 1987 - Aug 1989

Registrar in Haematology, Hammersmith and Ealing Hospitals.

Two year post providing broad experience in clinical and laboratory haematology working for Professors Luzzatto, Goldman, Catovsky, Barrett and Drs. Hegde, Hows and Lewis.

Attachments to bone marrow transplant and acute leukaemia unit, radioisotope unit, diagnostic laboratory, blood transfusion laboratory and wide experience of outpatient haematology.

Sept 1989 - May 1990

Clinical Research Fellow, Leukaemia Research Fund, Chester Beatty Laboratory, London.

Nine months working with Dr Myrtle Gordon studying chemotherapy induced stem cell mobilisation in mice. Experience gained in haematopoietic cell culture techniques including long-term repopulating stem cell assays in mice.

May 1990 - Jan 1994

Wellcome Trust Clinical Fellow (Honorary Senior Registrar), MRC Molecular Haematology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, OX3 9DU.

Three and a half years studying for a D.Phil thesis on "normal and abnormal regulation of α globin gene regulation" with Dr. Douglas Higgs. Particular interests included the role of chromatin structure in regulation of gene expression, telomere structure, and the syndrome of acquired HbH disease.

Feb 1994 - Aug 1996

Senior Fellow, Department of Haematology, University of Washington Medical Centre, Seattle, Washington.

A two and a half year attachment including eighteen months working as a post-doctoral student in the laboratory of Dr Thalia Papayannopoulou studying the biological basis of stem cell mobilisation and homing. During this period experience was also gained in the out-patient management of patients with a wide range of haematological disorders including haematological malignancies, haemoglobinopathies and coagulation disorders. The last year of the Fellowship consisted of a clinical rotation through the Fred Hutchinson Cancer Centre, the University of Washington Medical Centre, Harborview Hospital and the Puget Sound Blood Centre. This provided intensive training in

management of haematological malignancies, bone marrow transplantation, and general and consultative haematology.

Sept 1996 - Jan 1997

Bone Marrow Transplant Co-ordinator, Department of Haematology, Hammersmith Hospital, London.

Responsibility for in patient and out patient care of allogeneic and autologous bone marrow transplant patients. In addition extensive experience gained in non-transplant management of a wide range of haematological malignancies. The transplant co-ordinator also plays a significant role in designing treatment and research protocols in transplant related areas. This post involved participation in the general haematology on-call rota.

Feb 1997 - April 1998

Locum Consultant Haematologist, Hammersmith Hospital, London.

April 1998 - Oct 1999

Consultant Haematologist and Honorary Senior Lecturer, Dept of Haematology, Hammersmith Hospital, London.

Post included consultant responsibility on bone marrow transplant and leukaemia units. I also contributed to the development of clinical programmes in unrelated donor transplantation and the introduction of a reduced intensity conditioning regimen.

Nov 1999 - June 2004

Consultant Haematologist and Director of Stem Cell Transplant Unit, Queen Elizabeth Hospital, Birmingham, Honorary Reader in Bone Marrow Transplantation, University of Birmingham.

MEDICAL EXPERIENCE ABROAD:

1980

Six weeks working on Medical Unit at Wusikili Hospital, Kitwe, Zambia with Dr. Fisher.

1981

Six weeks working on Medical Unit at Baragwaneth Hospital, Soweto, South Africa with Professors Dubb and Barlow.

1988

Four weeks working at the MRC Unit, The Gambia with Dr. N. White performing a randomised trial on the treatment of cerebral malaria.

PAPERS:

1. Jenkins JA, Nineham R, **Craddock C**, Craig-McFeely P, Donaldson K, Leigh T, et al. Fibre and diabetes. *Lancet*. 1979;1(8113):434-5.
2. **Craddock C**. Prevention of coronary heart disease. *Oxford Medical Journal*. 1981.
3. Rayner HC, **Craddock C**. Reversible coma in Wernicke's encephalopathy. *Postgraduate Medical Journal*. 1985;61(722):1097.
4. Edwards R, **Craddock C**, Russell T, Finch RG. Influence of bacterial adherence to intravascular catheters on in-vitro antibiotic susceptibility. *Lancet*. 1986;1(8476):330-1.
5. Finch R, Whitby M, **Craddock C**, Holliday A, Martin J, Pilkington R. Clinical evaluation of treatment with ciprofloxacin. *European Journal of Clinical Microbiology*. 1986;5(2):257-9.
6. Finch RG, **Craddock C**, Kelly J, Deaney NB. Pharmacokinetic studies of imipenem: cilastatin in elderly patients. *The Journal of Antimicrobial Chemotherapy*. 1986;18 Suppl E:103-7.
7. **Craddock C**. CAPD peritonitis. *Lancet*. 1987;1(8545):1320-1.
8. **Craddock C**, Pasvol G, Bull R, Protheroe A, Hopkin J. Cardiorespiratory arrest and autonomic neuropathy in AIDS. *Lancet (London, England)*. 1987;2(8549):16-8.
9. **Craddock C**, Edwards R, Finch RG. Pseudomonas peritonitis in continuous ambulatory peritoneal dialysis: laboratory predictors of treatment failure. *The Journal of Hospital Infection*. 1987;10(2):179-86.
10. **Craddock C**, Richards NP, Powell RJ, Morgan AG. Novel C3 nephritic factor activity in the glomerulonephritis of staphylococcal endocarditis. *The Quarterly Journal of Medicine*. 1987;65(247):895-8.
11. Durham SR, **Craddock C**, Cookson WO, Benson MK. Increases in airway responsiveness to histamine precede allergen-induced late asthmatic responses. *The Journal of Allergy and Clinical Immunology*. 1988;82(5 Pt 1):764-70.
12. Cookson WO, **Craddock C**, Benson MK, Durham SR. Falls in peripheral eosinophil counts parallel the late asthmatic response. *The American Review of Respiratory Disease*. 1989;139(2):458-62.
13. Durham SR, Keenan J, Cookson WO, **Craddock C**, Benson MK. Diurnal variation in serum cortisol concentrations in asthmatic subjects after allergen inhalation. *Thorax*. 1989;44(7):582-5.
14. White NJ, Krishna S, Waller D, **Craddock C**, Kwiatkowski D, Brewster D. Open comparison of intramuscular chloroquine and quinine in children with severe chloroquine-sensitive falciparum malaria. *Lancet (London, England)*. 1989;2(8675):1313-6.
15. Waller D, Krishna S, **Craddock C**, Brewster D, Jammeh A, Kwiatkowski D, et al. The pharmacokinetic properties of intramuscular quinine in Gambian children with severe falciparum malaria. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1990;84(4):488-91.
16. Waller D, Crawley J, Nosten F, Chapman D, Krishna S, **Craddock C**, et al. Intracranial pressure in childhood cerebral malaria. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1991;85(3):362-4.

17. **Craddock C**, Apperley JF, Wright EG, Healy LE, Bennett CA, Evans M, et al. Circulating stem cells in mice treated with cyclophosphamide. *Blood*. 1992;80(1):264-9.
18. Vyas P, Vickers M, Simmonds D, Ayyub H, **Craddock C**, Higgs D. The structural and functional organization of the human alpha globin regulatory domain. *Cell*. 1993;69(5):781-793.
19. Krishna S, Waller DW, ter Kuile F, Kwiatkowski D, Crawley J, **Craddock C**, et al. Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1994;88(1):67-73.
20. **Craddock C**, Vyas P, Sharpe JA, Ayyub H, Wood WG, Higgs DR. Contrasting effects of alpha and beta globin regulatory elements on chromatin structure may be related to their different chromosomal environments. *The EMBO Journal*. 1995;14(8):1718-26.
21. Pondel MD, Murphy S, Pearson L, **Craddock C**, Proudfoot NJ. Sp1 functions in a chromatin-dependent manner to augment human alpha-globin promoter activity. *Proceedings of the National Academy of Sciences of the United States of America*. 1995;92(16):7237-41.
22. Waller D, Krishna S, Crawley J, Miller K, Nosten F, Chapman D, ter Kuile FO, **Craddock C**, Berry C, Holloway PA, et al. Clinical features and outcome of severe malaria in Gambian children. *Clinical Infectious Diseases*. 1995;21(3):577-87.
23. Flint J, Rochette J, **Craddock C**, Dode C, Vignes B, Horsley SW, et al. Chromosomal stabilisation by a subtelomeric rearrangement involving two closely related Alu elements. *Human Molecular Genetics*. 1996;5(8):1163-9.
24. **Craddock C**, Nakamoto B, Andrews RG, Priestley GV, Papayannopoulou T. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. *Blood*. 1997;90(12):4779-88.
25. **Craddock C**, Nakamoto B, Elices M, Papayannopoulou T. The role of CS1 moiety of fibronectin in VLA mediated haemopoietic progenitor trafficking. *British Journal of Haematology*. 1997;97(1):15-21.
26. Papayannopoulou T, **Craddock C**. Homing and trafficking of hemopoietic progenitor cells. *Acta Haematologica*. 1997;97(1-2):97-104.
27. Apperley JF, Dazzi F, **Craddock C**, Goldman JM. Immunotherapy for chronic myeloid leukaemia. *Hematology and Cell Therapy*. 1998;40(5):229-32.
28. Kanfer EJ, McGuigan D, Samson D, Abboudi Z, Abrahamson G, Apperley JF, Chilcott S, **Craddock C**, et al. High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels. *British Journal of Cancer*. 1998;78(7):928-32.
29. **Craddock C**. Non-myeloablative stem cell transplants. *Current Opinion in Hematology*. 1999;6(6):383-7.
30. Stocchi R, Szydlo R, **Craddock C**, Kanfer E, Apperley JF, Goldman JM, et al. A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation. *Bone Marrow Transplantation*. 1999;23(7):705-9.

31. **Craddock C**, Bardy P, Kreiter S, Johnston R, Apperley J, Marks D, et al. Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen. *British Journal of Haematology*. 2000;111(3):797-800.
32. **Craddock C**, Szydlo RM, Klein JP, Dazzi F, Olavarria E, van Rhee F, et al. Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. *Blood*. 2000;96(1):86-90.
33. Dazzi F, Szydlo RM, **Craddock C**, Cross NC, Kaeda J, Chase A, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. *Blood*. 2000;95(1):67-71.
34. Dazzi F, Szydlo RM, Cross NC, **Craddock C**, Kaeda J, Kanfer E, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. *Blood*. 2000;96(8):2712-6.
35. Klein JP, Szydlo RM, **Craddock C**, Goldman JM. Estimation of current leukaemia-free survival following donor lymphocyte infusion therapy for patients with leukaemia who relapse after allografting: application of a multistate model. *Statistics in Medicine*. 2000;19(21):3005-16.
36. Olavarria E, Hassan M, Eades A, Nilsson C, Timms A, Matthews J, **Craddock C**, et al. A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. *Leukemia*. 2000;14(11):1954-9.
37. Olavarria E, Kanfer E, Szydlo R, O'Brien S, **Craddock C**, Apperley J, et al. High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience. *British Journal of Haematology*. 2000;108(4):769-77.
38. Olavarria E, Parker S, **Craddock C**, Philpott N, Tiniakou M, Chase A, et al. Collection of Ph-negative progenitor cells from interferon responsive patients with chronic myeloid leukemia: effect of granulocyte-colony-stimulating factor mobilization. *Haematologica*. 2000;85(6):647-52.
39. **Craddock C**, Szydlo RM, Dazzi F, Olavarria E, Cwynarski K, Yong A, et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. *British Journal of Haematology*. 2001;112(1):228-36.
40. Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley J, Goldman J, **Craddock C**, Moss PA. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. *Blood*. 2001;97(5):1232-40.
41. Cwynarski K, Goulding R, Pocock C, Dazzi F, **Craddock C**, Kaeda J, et al. Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions. *Bone Marrow Transplantation*. 2001;28(6):581-6.

42. Lush RJ, Haynes AP, Byrne J, Cull GM, Carter GI, Pagliuca A, Parker JE, Mufti G, Mahendra P, **Craddock C**, et al. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. *Cytotherapy*. 2001;3(3):203-10.
43. Mughal TI, Yong A, Szydlo RM, Dazzi F, Olavarria E, van Rhee F, Kaeda J, Cross NC, **Craddock C**, Kanfer E, Apperley J, Goldman JM. Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. *British Journal of Haematology*. 2001;115(3):569-74.
44. Olavarria E, Kanfer E, Szydlo R, Kaeda J, Rezvani K, Cwynarski K, Pocock C, Dazzi F, **Craddock C**, Apperley JF, Cross NC, Goldman JM. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. *Blood*. 2001;97(6):1560-5.
45. Pawson R, Potter MN, Theocharous P, Lawler M, Garg M, Yin JA, Rezvani K, **Craddock C**, Rassam S, Prentice HG. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant. *British Journal of Haematology*. 2001;115;(3):622-9.
46. Pocock C, Szydlo R, Davis J, de La Fuente J, **Craddock C**, Cwynarski K, et al. Stem cell transplantation for chronic myeloid leukaemia: the role of infused marrow cell dose. *The Hematology Journal*. 2001;2(4):265-72.
47. Branson K, Chopra R, Kottaridis PD, McQuaker G, Parker A, Schey S, Chakraverty RK, **Craddock C**, et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 2002;20(19):4022-31.
48. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, Chakraverty R, Marshall T, Osman H, Mahendra P, **Craddock C**, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. *Blood*. 2002;99(12):4357-63.
49. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuert S, Geary J, Thuraisundaram D, Branson K, Chakrabarti S, Mahendra P, **Craddock C**, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. *Blood*. 2002;99(3):1071-8.
50. **Craddock C**, Hochhauser D. Realising the potential of targeted therapies in oncology. *Lancet*. 2002;360(9331):424-5.
51. Cwynarski K, **Craddock C**, Cobbold M, Apperley J, Goldman J. Survival after bone-marrow transplantation. *Lancet*. 2002;359(9309):887-8.
52. Grimwade D, Outram SV, Flora R, Ings SJ, Pizzey AR, Morilla R, **Craddock C**, Linch DC, Solomon E. The T-lineage-affiliated CD2 gene lies within an open chromatin environment in acute promyelocytic leukemia cells. *Cancer Research*. 2002;62(16):4730-5.

53. Olavarria E, **Craddock C**, Dazzi F, Marin D, Markt S, Apperley JF, et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. *Blood*. 2002;99(10):3861-2.
54. Perez-Simon JA, Kottaridis PD, Martino R, **Craddock C**, Caballero D, Chopra R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. *Blood*. 2002;100(9):3121-7.
55. Spanswick VJ, **Craddock C**, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. *Blood*. 2002;100(1):224-9.
56. **Craddock C**, Augustson B, Basu S. Imatinib or transplant for chronic myeloid leukaemia. *Lancet*. 2003;362(9378):173 (letter).
57. **Craddock C**, Grigg AP. T-cell depletion does not necessarily compromise donor stem cell engraftment in patients receiving reduced-intensity conditioning regimens. *Bone Marrow Transplantation*. 2003;31(12):1177 (letter).
58. Ma YT, Weatherby SJ, Rao DG, Winer JB, **Craddock C**, Williams AC. Facial flushing and localized Castleman's disease: an extension of the POEMS syndrome phenotype. *Journal of Internal Medicine*. 2003;253(2):247-8.
59. Moss PA, Cobbold M, **Craddock C**. The cellular immunotherapy of viral infection. *Transfusion Medicine*. 2003;13(6):405-15.
60. Tauro S, McMullan D, Griffiths M, **Craddock C**, Mahendra P. High-hyperdiploidy in Philadelphia positive adult acute lymphoblastic leukaemia: case-series and review of literature. *Bone Marrow Transplantation*. 2003;31(9):763-6.
61. Tauro S, Shankaranarayana P, Nitu-Whalley IC, Duncan N, Begum G, Craig JJ, Marcus RE, **Craddock C**, Mahendra P. Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia. *Bone Marrow Transplantation*. 2003;32(3):273-8.
62. Clark FJ, Gregg R, Piper K, Dunnion D, Freeman L, Griffiths M, Begum G, Mahendra P, **Craddock C**, Moss P, Chakraverty R. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. *Blood*. 2004;103(6):2410-6.
63. Cook MA, Milligan DW, Fegan CD, Darbyshire PJ, Mahendra P, **Craddock C**, et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. *Blood*. 2004;103(4):1521-6.
64. Faulkner RD, **Craddock C**, Byrne JL, Mahendra P, Haynes AP, Prentice HG, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. *Blood*. 2004;103(2):428-34.
65. Mehta P, Augustson B, Krishnamurthy S, Jacob A, Roy D, Olliff J, Cook M, **Craddock C**, Mahendra P. Successful allogeneic haematopoietic stem cell transplantation in patients with poor-risk leukaemia and prior invasive fungal infection. *Bone Marrow Transplantation*. 2004;34(9):825-6.
66. Morris E, Thomson K, **Craddock C**, Mahendra P, Milligan D, Cook G, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. *Blood*. 2004;104(13):3865-71.

67. Russell NH, Szydlo R, McCann S, Potter MN, **Craddock C**, Towlson K, et al. The use of a national transplant registry to benchmark transplant outcome for patients undergoing autologous and allogeneic stem cell transplantation in the United Kingdom and Ireland. *British Journal of Haematology*. 2004;124(4):499-503.
68. Wandroo F, Auguston B, Cook M, **Craddock C**, Mahendra P. Successful use of Campath-1H in the treatment of steroid refractory liver GvHD. *Bone Marrow Transplantation*. 2004;34(3):285-7.
69. Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, **Craddock C**, Turner BM. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. *Leukemia*. 2005;19(10):1751-9.
70. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, Assenmacher M, Billingham L, Steward C, Crawley C, Olavarria E, Goldman J, Chakraverty R, Mahendra P, **Craddock C**, Moss PA. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. *The Journal of Experimental Medicine*. 2005;202(3):379-86.
71. **Craddock C**, Tauro S, Moss P, Grimwade D. Biology and management of relapsed acute myeloid leukaemia. *British Journal of Haematology*. 2005;129(1):18-34.
72. Griffiths M, Mason J, Rindl M, Akiki S, McMullan D, Stinton V, Powell H, Curtis A, Bown N, **Craddock C**. Acquired isodisomy for chromosome 13 is common in AML, and associated with FLT3-ITD mutations. *Leukemia*. 2005;19(12):2355-8.
73. Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, **Craddock C**, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. *Lancet*. 2005;365(9475):1934-41.
74. Raj K, Narayanan S, Auguston B, Ho A, Mehta P, Duncan N, Tauro S, Mahendra P, **Craddock C**, Mufti G. Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation. *Bone Marrow Transplantation*. 2005;35(3):299-301.
75. Tauro S, **Craddock C**, Peggs K, Begum G, Mahendra P, Cook G, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 2005;23(36):9387-93.
76. Chantry AD, Snowden JA, **Craddock C**, Peggs K, Roddie C, Craig JJ, et al. Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study. *Biology of Blood and Marrow Transplantation: journal of the American Society for Blood and Marrow Transplantation*. 2006;12(12):1310-7.
77. Cook M, Briggs D, **Craddock C**, Mahendra P, Milligan D, Fegan C, et al. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. *Blood*. 2006;107(3):1230-2.
78. Duarte RF, Pamphilon D, Cornish J, Shaw BE, Samson D, **Craddock C**, et al. Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London - 2005. *Bone Marrow Transplantation*. 2006;37(10):901-8.

79. Duncan N, **Craddock C**. Optimizing the use of cyclosporin in allogeneic stem cell transplantation. *Bone Marrow Transplantation*. 2006;38(3):169-74.
80. Karanth M, Begum G, Cook M, Lawson S, Porter C, Lister N, Gray J, Darbyshire P, **Craddock C**, Mahendra P. Increased acute GvHD and higher transplant-related mortality in non-caucasians undergoing standard sibling allogeneic stem cell transplantation. *Bone Marrow Transplantation*. 2006;37(4):419-23.
81. Kochethu G, Clark FJ, **Craddock C**. Pertussis: should we vaccinate post transplant? *Bone Marrow Transplantation*. 2006;37(8):793-4.
82. Milligan DW, Grimwade D, Cullis JO, Bond L, Swirsky D, **Craddock C**, et al. Guidelines on the management of acute myeloid leukaemia in adults. *British Journal of Haematology*. 2006;135(4):450-74.
83. **Craddock C**. Molecularly targeted therapy in myeloid leukaemias. *Clinical Medicine*. 2007;7(6):632-5.
84. Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP, Lennard AL, Pallan L, Arrazi JM, Perz JB, O'Shea D, Goldman JM, Apperley JF, **Craddock C**. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. *Blood*. 2007;110(13):4614-7.
85. Piper KP, Horlock C, Curnow SJ, Arrazi J, Nicholls S, Mahendra P, **Craddock C**, Moss PA. CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation. *Blood*. 2007;110(12):3827-32.
86. **Craddock C**. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML. *Bone Marrow Transplantation*. 2008;41(5):415-23.
87. Shaw BE, Mufti GJ, Mackinnon S, Cavenagh JD, Pearce RM, Towlson KE, Apperley JF, Chakraverty R, **Craddock C**, et al. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. *Bone Marrow Transplantation*. 2008;42(12):783-9.
88. Tholouli E, Liakopoulou E, Greenfield HM, Shaw BE, Tauro S, Byrne JL, Dennis M, Burthem J, Lucas GS, **Craddock C**, Russell NH, Liu Yin JA. Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia. *British Journal of Haematology*. 2008;142(2):318-20.
89. Goardon N, Nikolousis E, Sternberg A, Chu WK, **Craddock C**, Richardson P, et al. Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes. *Haematologica*. 2009;94(8):1160-3.
90. Khanim FL, Bradbury CA, Arrazi J, Hayden RE, Rye A, Basu S, MacWhannell A, Sawers A, Griffiths M, Cook M, Freeman S, Nightingale KP, Grimwade D, Falciani F, Turner BM, Bunce CM, **Craddock C**. Elevated FOSB-expression; a potential marker of valproate sensitivity in AML. *British Journal of Haematology*. 2009;144(3):332-41.
91. Malladi RK, Peniket AJ, Littlewood TJ, Towlson KE, Pearce R, Yin J, Cavenagh JD, **Craddock C**, et al. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML. *Bone Marrow Transplantation*. 2009;43(9):709-15.

92. Nicholls S, Piper KP, Mohammed F, Dafforn TR, Tenzer S, Salim M, Mahendra P, **Craddock C**, et al. Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition. *Proceedings of the National Academy of Sciences of the United States of America*. 2009;106(10):3889-94.
93. Patel B, Kirkland KE, Szydlo R, Pearce RM, Clark RE, **Craddock C**, et al. Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. *Haematologica*. 2009;94(10):1399-406.
94. Popat R, Oakervee H, Williams C, Cook M, **Craddock C**, Basu S, et al. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. *British Journal of Haematology*. 2009;144(6):887-94.
95. Pourghesari B, Piper KP, McLarnon A, Arrazi J, Bruton R, Clark F, Cook M, Mahendra P, **Craddock C**, Moss PA. Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT. *Bone Marrow Transplantation*. 2009;43(11):853-61.
96. Shaw BE, Veys P, Pagliuca A, Addada J, Cook G, **Craddock C**, et al. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms. *Bone Marrow Transplantation*. 2009;44(1):7-12.
97. Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K, Morris E, Orchard K, Rule S, Russell N, **Craddock C**, et al. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation*. 2010;16(10):1419-27.
98. **Craddock C**, Anson J, Chu P, Dodgson A, Duncan N, Gomez C, et al. Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex. *Expert Opinion on Drug Safety*. 2010;9(1):139-47.
99. **Craddock C**, Nagra S, Peniket A, Brookes C, Buckley L, Nikolousis E, et al. Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. *Haematologica*. 2010;95(6):989-95.
100. Duncan N, Arrazi J, Nagra S, Cook M, Thomson AH, **Craddock C**. Prediction of intravenous cyclosporine area under the concentration-time curve after allogeneic stem cell transplantation. *Therapeutic Drug Monitoring*. 2010;32(3):353-8.
101. Goodyear O, Agathangelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, Vyas P, Cavenagh J, Stankovic T, Moss P, **Craddock C**. Induction of a CD8+ T-cell Response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. *Blood*. 2010;116(11):1908-18.
102. Grant H, Jiang X, Stebbing J, Foroni L, **Craddock C**, Griffiths M, et al. Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype. *Leukemia*. 2010;24(10):1817-21.

103. Li-Wan-Po A, Farndon P, **Craddock C**, Griffiths M. Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example. *European Journal of Clinical Pharmacology*. 2010;66(4):369-74.
104. McLarnon A, Piper KP, Goodyear OC, Arrazi JM, Mahendra P, Cook M, Clark F, Pratt G, **Craddock C**, Moss PA. CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect. *Haematologica*. 2010;95(9):1572-8.
105. Murray JA, Khanim FL, Hayden RE, **Craddock C**, Holyoake TL, Jackson N, et al. Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML). *British Journal of Haematology*. 2010;149(1):65-9.
106. Stewart WA, Pearce R, Kirkland KE, Bloor A, Thomson K, Apperley J, McQuaker G, Marks DI, **Craddock C**, et al. The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. *Bone Marrow Transplantation*. 2010;45(11):1587-93.
107. **Craddock C**. Enshrining donor rights and optimizing patient outcome in unrelated donor transplantation. *Bone Marrow Transplantation*. 2011;46(1):17.
108. **Craddock C**. Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignancies. *Cytotherapy*. 2011;13(5):516-7.
109. **Craddock C**, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H, et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. *Leukemia*. 2011;25(5):808-13.
110. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, Woll P, Mead A, Alford KA, Rout R, Chaudhury S, Gilkes A, Knapper S, Beldjord K, Begum S, Rose S, Geddes N, Griffiths M, Standen G, Sternberg A, Cavenagh J, Hunter H, Bowen D, Killick S, Robinson L, Price A, Macintyre E, Virgo P, Burnett A, **Craddock C**, Enver T, Jacobsen SE, Porcher C, Vyas P. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. *Cancer Cell*. 2011;19(1):138-52.
111. Hill VK, Dunwell TL, Catchpoole D, Krex D, Brini AT, Griffiths M, **Craddock C**, Maher ER, Latif F. Frequent epigenetic inactivation of KIBRA, an upstream member of the Salvador/Warts/Hippo (SWH) tumor suppressor network, is associated with specific genetic event in B-cell acute lymphocytic leukemia. *Epigenetics*. 2011;6(3):326-32.
112. Novitzky-Basso I, **Craddock C**. Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia. *European Journal of Haematology*. 2011;86(6):548-9.
113. Shaw BE, Apperley JF, Russell NH, **Craddock C**, Liakopoulou E, Potter MN, et al. Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease. *British Journal of Haematology*. 2011;153(2):244-52.
114. Bokhari SW, Watson L, Nagra S, Cook M, Byrne JL, **Craddock C**, et al. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoietic progenitor cell transplantation. *Bone Marrow Transplantation*. 2012;47(4):528-34.

115. Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L, Hunter AE, Yin J, **Craddock C**, Dufva IH, Wheatley K, Milligan D. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. *Journal of Clinical Oncology*. 2012;30(32):3924-31.
116. Croudace JE, Inman CF, Abbotts BE, Nagra S, Nunnick J, Mahendra P, **Craddock C**, Malladi R, Moss PA. Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD. *Blood*. 2012;120(20):4246-55.
117. Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G, Nunnick J, Khanum R, Raghavan M, Cook M, Snowden JA, Griffiths M, Russell N, Yin J, Crawley C, Cook G, Vyas P, Moss P, Malladi R, **Craddock C**. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). *Blood*. 2012;119(14):3361-9.
118. Nagler A, Labopin M, Shimoni A, Niederwieser D, Mufti GJ, Zander AR, Arnold R, Greinix H, Cornelissen JJ, Jackson GH, **Craddock C**, et al. Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*. 2012;18(9):1422-9.
119. Spanswick VJ, Lowe HL, Newton C, Bingham JP, Bagnobianchi A, Kiakos K, **Craddock C**, Ledermann JA, Hochhauser D, Hartley JA. Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples. *BMC cancer*. 2012;12:436.
120. Cobbold M, De La Peña H, Norris A, Polefrone JM, Qian J, English AM, Cummings KL, Penny S, Turner JE, Cottine J, Abelin JG, Malaker SA, Zarling AL, Huang HW, Goodyear O, Freeman SD, Shabanowitz J, Pratt G, **Craddock C**, Williams ME, Hunt DF, Engelhard VH. MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. *Science Translational Medicine*. 2013;5(203):203ra125.
121. **Craddock C**. Pharmacological methods to reduce disease recurrence. *Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program*. 2013;2013:63-9.
122. **Craddock C**, Quek L, Goardon N, Freeman S, Siddique S, Raghavan M, et al. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. *Leukemia*. 2013;27(5):1028-36.
123. Giebel S, Labopin M, Mohty M, Mufti GJ, Niederwieser D, Cornelissen JJ, Janssen JJ, Milpied N, Vindelov L, Petersen E, Arnold R, Bacigalupo A, Blaise D, **Craddock C**, Nagler A, Frassoni F, Sadus-Wojciechowska M, Rocha V. The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplantation*. 2013;48(2):238-42.
124. Jantunen E, Boumendil A, Finel H, Luan JJ, Johnson P, Rambaldi A, Haynes A, Duchosal MA, Bethge W, Biron P, Carlson K, **Craddock C**, et al. Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. *Blood*. 2013;121(13):2529-32.

125. Lown RN, Tulpule S, Russell NH, **Craddock C**, Roest R, Madrigal JA, et al. Subsequent donation requests among 2472 unrelated hematopoietic progenitor cell donors are associated with bone marrow harvest. *Haematologica*. 2013;98(12):1956-63.
126. Medd P, Nagra S, Hollyman D, **Craddock C**, Malladi R. Cryopreservation of allogeneic PBSC from related and unrelated donors is associated with delayed platelet engraftment but has no impact on survival. *Bone Marrow Transplantation*. 2013;48(2):243-8.
127. Medd PG, Peniket AJ, Littlewood TJ, Pearce R, Perry J, Kirkland KE, Shaw BE, Potter MN, **Craddock C**, et al. Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study. *Bone Marrow Transplantation*. 2013;48(7):982-7.
128. Nikolousis E, Robinson S, Nagra S, Brookes C, Kinsella F, Tauro S, Jeffries S, Griffiths M, Mahendra P, Cook M, Paneesha S, Lovell R, Kishore B, Chaganti S, Malladi R, Raghavan M, Moss P, Milligan D, **Craddock C**. Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant. *Leukemia Research*. 2013;37(5):561-5.
129. Avivi I, Canals C, Vernant JP, Wulf G, Nagler A, Hermine O, Petersen E, Yakoub-Agha I, **Craddock C**, et al. Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma. *Bone Marrow Transplantation*. 2014;49(5):671-8.
130. Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, **Craddock C**, et al. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplantation*. 2014;49(3):389-96.
131. Fox CP, Burns D, Parker AN, Peggs KS, Harvey CM, Natarajan S, Marks DI, Jackson B, Chakupurakal G, Dennis M, Lim Z, Cook G, Carpenter B, Pettitt AR, Mathew S, Connelly-Smith L, Yin JA, Viskaduraki M, Chakraverty R, Orchard K, Shaw BE, Byrne JL, Brookes C, **Craddock C**, Chaganti S. EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. *Bone Marrow Transplantation*. 2014;49(2):280-6.
132. Malottki K, Biswas M, Deeks JJ, Riley RD, **Craddock C**, Johnson P, Billingham L. Stratified medicine in European Medicines Agency licensing: a systematic review of predictive biomarkers. *BMJ Open*. 2014;4(1):e004188.
133. Uttenthal B, Martinez-Davila I, Ivey A, **Craddock C**, Chen F, Virchis A, et al. Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. *British Journal of Haematology*. 2014;164(3):366-75.

134. Yeshurun M, Labopin M, Blaise D, Cornelissen JJ, Sengeloev H, Vindelov L, Kuball J, Chevallier P, **Craddock C**, et al. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Cancer*. 2014;120(6):855-63.
135. Ringdén O, Labopin M, Solders M, Beelen D, Arnold R, Ehninger G, Milpied N, Niederwieser D, Hamladji RM, Kyrzcz-Krzemien S, Ganser A, Socié G, Stelljes M, Volin L, **Craddock C**, Mohty M; Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia? *Transplantation*. 2014;98;569-77.
136. Ali S, Jones GL, Culligan DJ, Marsden PJ, Russell N, Embleton ND, **Craddock C**; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy. *British Journal of Haematology*. 2015;170(4):487-95.
137. Bradbury C, Houlton AE, Akiki S, Gregg R, Rindl M, Khan J, Ward J, Khan N, Griffiths M, Nagra S, Hills R, Burnett A, Russell N, Vyas P, Grimwade D, **Craddock C**, Freeman SD. Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia. *Leukemia*. 2015;29(4):988-91.
138. Brissot E, Labopin M, Beckers MM, Socie G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele GJ, **Craddock C**, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. *Haematologica*. 2015;100(3):392-9.
139. Nikolousis E, Nagra S, Pearce R, Perry J, Kirkland K, Byrne J, Dignan F, Tholouli E, Gilleece M, Russell N, Littlewood T, Cook M, Peniket A, Shaw BE, Cook G, **Craddock C**. Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study. *Bone Marrow Transplant*. 2015;50: 82-6
140. Burns DM, Tierney R, Shannon-Lowe C, Croudace J, Inman CF, Abbotts B, Nagra S, Fox CP, Chaganti S, **Craddock C**, et al. Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event. *Blood*. 2015;126(25):2665-75.
141. Loke J, Khan JN, Wilson JS, **Craddock C**, Wheatley K. Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. *Annals of Hematology*. 2015;94(3):361-73.
142. Raeiszadeh M, Pachnio A, Begum J, **Craddock C**, Moss P, Chen FE. Characterization of CMV-specific CD4+ T-cell reconstitution following stem cell transplantation through the use of HLA Class II-peptide tetramers identifies patients at high risk of recurrent CMV reactivation. *Haematologica*. 2015;100(8):e318-22.

143. Robin M, Ruggeri A, Labopin M, Niederwieser D, Tabrizi R, Sanz G, Bourhis JH, van Biezen A, Koenecke C, Blaise D, Tischer J, **Craddock C**, et al. Comparison of unrelated cord blood and peripheral blood stem cell transplantation in adults with myelodysplastic syndrome after reduced-intensity conditioning regimen: a collaborative study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party. *Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation*. 2015;21(3):489-95.
144. Russell NH, Kjeldsen L, **Craddock C**, et al. A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia. *Leukemia*. 2015;29(7):1478-84.
145. Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F, Esteve J, Giebel S, Gorin NC, Schmid C, Polge E, Aljurf M, Kroger N, **Craddock C**, et al. Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 2015;33(28):3144-51.
146. Vyas P, Appelbaum FR, **Craddock C**. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. *Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation*. 2015;21(1):8-15.
147. Passweg JR, Labopin M, Cornelissen J, Volin L, Socié G, Huynh A, Tabrizi R, Wu D, **Craddock C**, et al. Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplant*. 2015;50:1063-8.
148. Peffault de Latour R, Labopin M, Cornelissen J, Vigouroux S, **Craddock C**, et al. In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available? *Bone Marrow Transplant*. 2015;50:1411-5.
149. Loke JC, Akiki S, Borrow J, Ewing J, Bokhari SW, Chandra D, Arrazi J, Hazlewood P, Arthur K, Walsh J, Membwange Y, Wandroo FA, Watts A, Borg A, Brock K, Ferguson P, **Craddock C**, Griffiths M, Raghavan M. Acquired isodisomy on chromosome 13 at diagnosis results in impaired overall survival in patients with FLT3-ITD mutant acute myeloid leukaemia. *Leukemia* 2015;29:2404-7.
150. Hall S, Danby R, Osman H, Peniket A, Rocha V, **Craddock C**, Murphy M, Chaganti S. Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a U.K. dual centre experience. *Transfusion Medicine*. 2015;25:418-23.
151. Pigneux A, Labopin M, Maertens J, Cordonnier C, Volin L, Socié G, Blaise D, **Craddock C**, et al. Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML). *Leukemia*. 2015;29:2375-81

152. **Craddock C**, Jilani N, Siddique S, Yap C, Khan J, Nagra S, et al. Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial. *Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation*. 2016;22(2):385-90.
153. **Craddock C**, Labopin M, Robin M, Finke J, Chevallier P, Yakoub-Agha I, Bourhis JH, Sengelov H, Blaise D, Luft T, Hallek M, Kroger N, Nagler A, Mohty M. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. *Haematologica*. 2016;101(7):879-83.
154. Giebel S, Labopin M, Ibatci A, Browne P, Czerw T, Socie G, Unal A, Kyrz-Krzemien S, Bacigalupo A, Goker H, Potter M, Furness CL, McQuaker G, Beelen D, Milpied N, Campos A, **Craddock C**, Nagler A, Mohty M. Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT. *The Oncologist*. 2016;21(3):377-83.
155. Savani BN, Labopin M, Kroger N, Finke J, Ehninger G, Niederwieser D, Schwerdtfeger R, Bunjes D, Glass B, Socié G, Ljungman P, **Craddock C**, et al. Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia a report from the Acute Leukemia Working Party of the EBMT. *Haematologica*. 2016;101(6):773-80.
156. Snowden JA, Danby R, Ruggeri A, Marks DI, Hough RE, Pagliuca A, Potter M, Russell N, **Craddock C**, et al. Unrelated Cord Blood Transplantation in adults: evolution, experience and long-term outcomes in the UK National Health Service: a retrospective analysis on behalf of the British Society of Blood and Marrow Transplantation and Eurocord. *British Journal of Haematology*. 2016;172(3):478-81.
157. Ferguson P, Hills RK, Grech A, Betteridge S, Kjeldsen L, Dennis M, Vyas P, Goldstone AH, Milligan D, Clark RE, Russell NH, **Craddock C**; UK NCRI AML Working Group. An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. *Haematologica*. 2016;101(11):1351-8.
158. Potter VT, Iacobelli S, van Biezen A, Maertens J, Bourhis JH, Passweg JR, Yakhoub-Agha I, Tabrizi R, Bay JO, Chevallier P, Chalandon Y, Huynh A, Cahn JY, Ljungman P, **Craddock C**, et al. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research. *Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation*. 2016;22(9):1615-20.
159. Burns DM, Rana S, Martin E, Nagra S, Ward J, Osman H, Bell AI, Moss P, Russell NH, **Craddock C**, Fox CP, Chaganti S. Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT. *Bone Marrow Transplant*. 2016;51:825-32.

160. Hough R, Danby R, Russell N, Marks D, Veys P, Shaw B, Wynn R, Vora A, Mackinnon S, Peggs KS, Crawley C, **Craddock C**, et al. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. *British Journal of Haematology*. 2016;172:360-70.
161. Penack O, Tridello G, Hoek J, Socié G, Blaise D, Passweg J, Chevallier P, **Craddock C**, et al. Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties. *Bone Marrow Transplant*. 2016;51:418-23.
162. Lee JB, Billen A, Lown RN, Potter MN, **Craddock C** et al. Exacerbation of IgA nephropathy following G-CSF administration for PBSC collection: suggestions for better donor screening. *Bone Marrow Transplant*. 2016;51:286-7.
163. Quek L, Otto GW, Garnett C, Lhermitte L, Karamitros D, Stoilova B, Lau IJ, Doondea J, Usukhbayar B, Kennedy A, Metzner M, Goardon N, Ivey A, Allen C, Gale R, Davies B, Sternberg A, Killick S, Hunter H, Cahalin P, Price A, Carr A, Griffiths M, Virgo P, Mackinnon S, Grimwade D, Freeman S, Russell N, **Craddock C**, et al. Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. *The Journal of Experimental Medicine*. 2016 25;213(8):1513-35.
164. Rubio MT, Savani BN, Labopin M, Polge E, Niederwieser D, Ganser A, Schwerdtfeger R, Ehninger G, Finke J, Renate A, **Craddock C**, et al. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party. *Journal of Haematology & Oncology*. 2016;9(1):65.
165. Saraceni F, Labopin M, Gorin NC, Blaise D, Tabrizi R, Volin L, Cornelissen J, Cahn JY, Chevallier P, **Craddock C**, et al. Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT. *Journal of Hematology & Oncology*. 2016;9(1):79.
166. Quek L, Ferguson P, Metzner M, Ahmed I, Kennedy A, Garnett C, Jeffries S, Walter C, Piechocki K, Timbs A, Danby R, Raghavan M, Peniket A, Griffiths M, Bacon A, Ward J, Wheatley K, Vyas P, and **Craddock C**. Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. *Blood Advances*. 2016;1:193-204.
167. Versluis J, Labopin M, **Craddock C**, et al. Alternative donors for allogeneic haematopoietic stem cell transplantation in poor-risk acute myeloid leukemia in CR1. *Blood Advances*. 2017;1:477-485.
168. Cathcart P, Craddock C, Stebbing J. Fasting: starving cancer. *Lancet Oncology*. 2017;18(4):431
169. Maggs L, Kinsella F, Chan YL, Eldershaw S, Murray D, Nunnick J, Bird J, **Craddock C** et al. The number of CD56dim NK cells in the graft has a major impact on risk of disease relapse following allo-HSCT. *Blood Advances*. 2017;1:1589-1597.

170. Piemontese S, Ciceri F, Labopin M, Arcese W, Kyrzcz-Krzemien S, Santarone S, Huang H, Beelen D, Gorin NC, **Craddock C**, et al. A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia. *J Hematol Oncol.* 2017;10(1):24-31.
171. Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, **Craddock C**, et al. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. *Bone Marrow Transplant.* 2017;52(2):209-215.
172. Russell NH, Freeman SD, **Craddock C**. Professor David Grimwade (1962-2016). *Bone Marrow Transplant.* 2017;52(2):171-172.
173. Green K, Pearce K, Sellar RS, Jardine L, Nicolson PL, Nagra S, Bigley V, Jackson G, Dickinson AM, Thomson K, Mackinnon S, **Craddock C**, Peggs KS, Collin M. The Impact of Alemtuzumab Scheduling on Graft Versus Host Disease Following Unrelated Donor Fludarabine and Melphalan Allografts. *Biol Blood Marrow Transplant.* 2017;23(5):805-812.
174. **Craddock C**. Improving Outcomes in High-Risk Myelodysplasia: Festina Lente. *J Clin Oncol.* 2017;35(24):2729-2731.
175. Onida F, de Wreede LC, van Biezen A, Eikema DJ, Byrne JL, Iori AP, Schots R, Jungova A, Schetelig J, Finke J, Veelken H, Johansson JE, **Craddock C**, et al. Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. *Br J Haematol.* 2017;177(5):759-765.
176. Ferguson P, **Craddock C**. Allogeneic transplantation in primary refractory AML. *Bone Marrow Transplant.* 2017;52(7):950-951.
177. Love SB, Brown S, Weir CJ, Harbron C, Yap C, Gaschler-Markefski B, Matcham J, Caffrey L, McKeivitt C, Clive S, **Craddock C**, Spicer J, Cornelius V. Embracing model-based designs for dose-finding trials. *Br J Cancer.* 2017 25;117(3):332-339.
178. Yap C, Billingham LJ, Cheung YK, **Craddock C**, O'Quigley J. (2017). Dose Transition Pathways: The missing link between complex dose-finding designs and simple decision-making. *Clin Cancer Res.* 2017;23(24):7440-7447.
179. Canaani J, Savani BN, Labopin M, Michallet M, **Craddock C**, et al. ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the Acute Leukemia Working Party of the EBMT. *Am J Hematol.* 2017;92(8):789-796.
180. **Craddock C**, Houlton AE, Quek LS, Ferguson P, Gbandi E, Roberts C, Metzner M, Garcia-Martin N, Kennedy A, Hamblin A, Raghavan M, Nagra S, Dudley L, Wheatley K, McMullin MF, Pillai SP, Kelly RJ, Siddique S, Dennis M, Cavenagh JD, Vyas P. Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature. *Clin Cancer Res.* 2017;23:6430-6440.
181. Poiré X, Labopin M, Polge E, Passweg J, **Craddock C**, et al. Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Haematologica.* 2018;103(2):256-265.

182. Chan YLT, Zuo J, Inman CF, Croft W, Begum J, Croudace J, Kinsella F, Maggs L, Nagra S, Nunnick J, Abbotts B, **Craddock C**, Malladi R, Moss P. NK cells produce high levels of IL-10 early after allogeneic stem cell transplantation and suppress development of acute GVHD. *Eur J Immunol*. 2018;48(2):316-329.
183. Cesaro S, Tridello G, Blijlevens N, Ljungman P, **Craddock C**, et al. Incidence, Risk Factors, and Long-term Outcome of Acute Leukemia Patients With Early Candidemia After Allogeneic Stem Cell Transplantation: A Study by the Acute Leukemia and Infectious Diseases Working Parties of European Society for Blood and Marrow Transplantation. *Clinical Journal of Infectious Diseases*. 2018;67(4):564-572.
184. Tozatto-Maio K, Giannotti F, Labopin M, Ruggeri A, Volt F, Paviglianiti A, Kenzey C, Hayashi H, Cornelissen J, Michallet M, Karakasis D, Deconinck E, Rohrlisch PS, de la Tour RP, Blaise D, Petersen E, D'Aveni M, Sengeloev H, Lamy T, Russell NH, Forcade E, **Craddock C**, et al. Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2018;24(8):1657-1663.
185. Garderet L, Ziagkos D, van Biezen A, Iacobelli S, Finke J, Maertens J, Volin L, Ljungman P, Chevallier P, Passweg J, Schaap N, Beelen D, Nagler A, Blaise D, Poiré X, Yakoub-Agha I, Lenhoff S, **Craddock C**, et al. Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. *Biol Blood Marrow Transplant*. 2018;24(3):507-513.
186. **Craddock C**, Versluis J, Labopin M, Socie G, Huynh A, Deconinck E, Volin L, Milpied N, Bourhis JH, Rambaldi A, Chevallier P, Blaise D, Manz M, Vellenga E, Vekemans MC, Maertens J, Passweg J, Vyas P, Schmid C, Löwenberg B, Ossenkoppele G, Mohty M, Cornelissen JJ, Nagler A. Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and HOVON-SAKK. *J Intern Med*. 2018;283(4):371-379.
187. **Craddock C**. Conditioning intensity in HCT for AML: the jury is still out. *Lancet Haematol*. 2018;(4):132-133.
188. Inman CF, Eldershaw SA, Croudace JE, Davies NJ, Sharma-Oates A, Rai T, Pearce H, Sirovica M, Chan YLT, Verma K, Zuo J, Nagra S, Kinsella F, Nunnick J, Amel-Kashipaz R, **Craddock C**, et al. Unique features and clinical importance of acute alloreactive immune responses. *JCI Insight*. 2018;17;3(10).
189. de Lima M, Oran B, Champlin RE, Papadopoulos EB, Giralt SA, Scott BL, William BM, Hetzer J, Laille E, Hubbell B, Skikne BS, **Craddock C**. CC-486 Maintenance After Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. *Biol Blood Marrow Transplant*. 2018;24(10):2017-2024.

190. Lorentino F, Labopin M, Bernardi M, Ciceri F, Socié G, Cornelissen JJ, Esteve J, Ruggeri A, Volin L, Yacoub-Agha I, **Craddock C**, et al. Comparable Outcomes of Haploidentical, 10/10 and 9/10 Unrelated Donor Transplantation in Adverse Karyotype AML in First Complete Remission. Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *American Journal of Hematology*. 2018;93(10):1236-1244.
191. **Craddock C**, Stem cell transplantation: Preventing Relapse of Transplant, *HemaSphere*: June 2018 - Volume 2 - Issue S2 - p 165–167
192. Brierley CK, Jones FM, Hanlon K, Peniket AJ, Hatton C, Collins GP, Schuh A, Medd P, Clark A, Ward J, Chaganti S, Malladi R, Parker A, **Craddock C**, Danby R, Rocha V. Impact of Graft-versus-Lymphoma Effect on Outcomes after Reduced Intensity Conditioned-Alemtuzumab Allogeneic Haematopoietic Stem Cell Transplantation for Patients with Mature Lymphoid Malignancies. *British Journal of Haematology*. 2019;184;547-557.
193. Mussai F, Wheat R, Sarrou E, Booth S, Stavrou V, Fultang L, Perry T, Kearns P, Cheng P, Keehsan K, **Craddock C**, De Santo C. Targeting the Arginine Metabolic Brake Enhances Immunotherapy for Leukaemia. *International Journal of Cancer*. Oct 15;145:2201-2208.
194. **Craddock C**. We do still transplant CML, don't we? *Hematology American Society of Hematology, Education Program*. 2018;(1):177–184.
195. **Craddock C**, Raghavan M. Which patients with acute myeloid leukemia in CR1 can be spared an allogeneic transplant? *Current Opinions in Hematology*. 2019;26(2):58-64.
196. **Craddock C**, Hölzer D, Komanduri K. Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia. *Bone Marrow Transplantation*.2019;54(1):6–16.
197. **Craddock C**, Slade D, De Santo C, Wheat R, Ferguson P, Hodgkinson A, Brock K, Cavenagh J, Ingram W, Dennis M, Malladi R, Siddique S, Mussai F, Yap C. Combination Lenalidomide and Azacitidine: a novel salvage therapy in patients who relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. *Journal of Clinical Oncology*. 2019;37: 580-588.
198. Robin M, Chevret S, Koster L, Wolschke C, Yakoub-Agha I, Bourhis JH, Chevallier P, Cornelissen JJ, Reményi P, Maertens J, Poiré X, **Craddock C**, et al. Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis. *Haematologica*. 2019;104(6):1230-1236.
199. Gagelmann N, Eikema DJ, Stelljes M, Beelen D, de Wreede L, Mufti G, Knelange NS, Niederwieser D, Friis LS, Ehnninger G, Nagler A, Yakoub-Agha I, Meijer E, Ljungman P, Maertens J, Kanz L, Lopez-Corral L, Brecht A, **Craddock C**, et al. Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. *Haematologica* 2019;104(5):929-936.
200. Daly AB, Cuthbert R, Finnegan D, Arnold C, **Craddock C**, McMullin MF. A comparison of inpatient and outpatient-based chemotherapy regimens for the treatment of acute myeloid leukaemia in the elderly. *Ulster Medical Journal*. 2019;88:25-29.

201. Kinsella FAM, Zuo J, Inman CF, Pearce H, Maggs L, Eldershaw SE, Chan YLT, Nunnick J, Nagra S, Griffiths M, **Craddock C**, et al. Mixed chimerism established by hematopoietic stem cell transplantation is maintained by host and donor T regulatory cells. *Blood Adv.* 2019 12;3(5):734-743.
202. Schmidt-Hieber M, Tridello G, Ljungman P, Mikulska M, Knelange N, Blaise D, Socié G, Volin L, Blijlevens N, Fegueux N, Yakoub-Agha I, Forcade E, Maertens J, Chevallier P, Passweg J, Cornelissen J, Russell N, **Craddock C**, et al. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the infectious diseases working party of EBMT. *Ann Hematol.* 2019;98(7): 1755-63
203. Robin M, Chevret S, Koster L, Wolschke C, Yakoub-Agha I, Bourhis JH, Chevallier P, Cornelissen JJ, Reményi P, Maertens J, Poiré X, **Craddock C** et al. Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis., *Haematologica.* 2019;104(6):1230-1236.
204. Kinsella FAM, Inman CF, Gudger A, Chan YT, Murray DJ, Zuo J, McIlroy G, Nagra S, Nunnick J, Holder K, Wall K, Griffiths M, **Craddock C**, et al. Very Early Lineage-specific Chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease. *Leuk Res.* 2019;83:106-173.
205. Gilleece MH, Labopin M, Savani BN, Yakoub-Agha I, Socié G, Gedde-Dahl T, Blaise D, Byrne JL, **Craddock C**, et al. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. *Leukemia.* 2019; in press.
206. Halaburda K, Labopin M, Mailhol A, Socié G, **Craddock C**, et al. Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Haematologica.* 2019; in press.
207. Mussai F, Wheat R, Sarrou E, Booth S, Stavrou V, Fultang L, Perry T, Kearns P, Cheng P, Keeshan K, **Craddock C**, De Santo C, Targeting the arginine metabolic brake enhances immunotherapy for leukaemia. *Int J Cancer.* 2019;15;145(8):2201-2208.
208. Fox TA, Horne GA, **Craddock C** et al. Trial re-investment to build better research for better impact. *Lancet.* 2019;24;394(10199):635-636.
209. Finazzi MC, Boschini C, **Craddock C**, Rambaldi A, Ward J, Malladi RK. Characteristics of graft-versus-host disease occurring after alemtuzumab-containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival. *Br J Haematol.* 2019 Nov 12. doi: 10.1111/bjh.16200. [Epub ahead of print]
210. Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, **Craddock C** et al Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients Bone Marrow Transplant. 2020 Jan 29. doi: 10.1038/s41409-020-0803-y. [Epub ahead of print]

211. Dillon R, Hills R, Freeman S, Potter N, Jovanovic J, Ivey A, Kanda AS, Runglall M, Foot N, Valganon M, Khwaja A, Cavenagh J, Smith M, Ommen HB, Overgaard UM, Dennis M, Knapper S, Kaur H, Taussig D, Mehta P, Raj K, Novitzky-Basso I, Nikolousis E, Danby R, Krishnamurthy P, Hill K, Finnegan D, Alimam S, Hurst E, Johnson P, Khan A, Salim R, **Craddock C** Molecular MRD status and outcome after transplantation in NPM1-mutated AML. *Blood*. 2020 Feb 27;135(9):680-688. doi: 10.1182/blood.2019002959.
212. Poiré X, Labopin M, Polge E, Volin L, Finke J, Ganser A, Blaise D, Yakoub-Agha I, Beelen D, Forcade E, Lioure B, Socié G, Niederwieser D, Labussière-Wallet H, Maertens J, Cornelissen J, **Craddock C**. The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation. *Am J Hematol*. 2020 Mar;95(3):282-294. doi: 10.1002/ajh.25714. Epub 2020 Jan 17.
213. Loke J, Malladi R, Moss P, **Craddock C** The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. *Br J Haematol*. 2020 Jan;188(1):129-146. doi: 10.1111/bjh.16355
214. Freeman S, Craddock C Less is not necessarily more: towards a rational selection of conditioning regimens in patients allografted for AML *J Clin Oncol*. 2020 Mar 2 do 101200/JCO.19.03161
215. Anthias C, Apperley J, Bloor A, Byrne J, Collin M, Crawley C, **Craddock C**, Finnegan D, Gilleece M, Gribben J, Hunter A, Hunter H, Koh M, Mackinnon S, Malladi R, Marks D, McQuaker G, Nikolousis M, Orchard K, Pavlu J, Peniket A, Potter M, Potter V, Robinson S, Russell N, Salim R, Snowden J, Thomson K, Tholouli E, Wilson K. Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative. *Bone Marrow Transplant*. 2020 Mar 24. [Epub ahead of print] No abstract available.
216. **Craddock C**, Janssen J, Wierzbowska A, et al Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO Guidelines Committee. *Ann Oncol*. 2020 Mar 11. S0923-7534(20)36079-8.[Epub ahead of print]
217. Anthias C, Apperley J, Bloor A, Byrne J, Collin M, Crawley C, **Craddock C**, Finnegan D, Gilleece M, Gribben J, Hunter A, Hunter H, Koh M, Mackinnon S, Malladi R, Marks D, McQuaker G, Nikolousis M, Orchard K, Pavlu J, Peniket A, Potter M, Potter V, Robinson S, Russell N, Salim R, Snowden J, Thomson K, Tholouli E, Wilson K. Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative. *Bone Marrow Transplant*. 2020 Sep, 55 (9): 1840-1843
218. Loke J, Labopin M, **Craddock C**, et al Impact of patient: donor HLA disparity on reduced-intensity conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT. *Bone Marrow Transplant*. 2020 Oct 2. Online ahead of print

CHAPTERS:

Higgs DR, **Craddock C**, Sharpe JA, Gourdon G, Vyas P, Raynham H, Ayyub H and Wood WG. Regulation of the human a globin gene cluster Sickle cell disease and thalassaemias: new trends in therapy (ed by Y Beuzard, B Lubin, J Rosa). pp 65-73 1995 Colloque INSERM/John Libbey Eurotext Ltd.

Higgs DR, Sharpe JA, Gourdon G, **Craddock C**, Vyas P, Picketts DJ, Barbour V, Ayyub H, and Wood WG. Expression of the human a globin cluster in transgenic mice Molecular Biology of Hemoglobin Switching (ed by G Stamatoyannopoulos). 1996 Intercept Andover Hants UK.

C Craddock and J Apperley. “Stem cell biology” Blood and Bone Marrow transplantation (EBMT Manual). 1999.

C Craddock. “Conditioning regimens and T-cell depletion” in Chronic myeloid leukaemia Biology and Treatment (ed by A Carella, G Daley, C Eaves, J Goldman, R Hehlmann). 2001.

C Craddock, R Chakraverty. “Stem cell transplantation” in Postgraduate Haematology (ed by AV Hoffbrand, E Tuddenham, D Catovsky). 5th Edition 2005.

C Craddock, G Perkins. “Multiple organ failure and intensive care” in Hematopoietic Stem Cell Transplantation in Clinical Practice (ed by Treleaven J, Barrett J). 2008.

C Craddock, R Chakraverty. “Stem cell transplantation” in Postgraduate Haematology (ed by AV Hoffbrand, E Tuddenham, D Catovsky). 6th Edition 2010.

C Craddock. Transplantation in Full Intensity and reduced Intensity Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: in Allogeneic Stem cell Transplantation Clinical Research and Practice (ed by MJ Laughlin and H Lazarus). 1st Edition 2010.

C Craddock, R Chakraverty. “Stem cell transplantation” in Postgraduate Haematology (ed by AV Hoffbrand, D Higgs, A Green). 6th Edition 2015.

C Craddock. Conditioning regimens: do they matter? “Current Concepts and Controversies in Hematopoietic Cell Transplantation” (ed by H M Lazarus, RP Gale, A Keating, A Bacigalupo, R Munker, K Atkinson). 2nd Edition 2015.

BOOKS:

Blood and Bone Marrow Transplantation (EBMT Manual). 1999 Associate Editor.

The Complete MRCP Part 2. H Benyon, C Marguerie, **C Craddock**, Churchill Livingstone.

The Complete MRCP Part 3. H Benyon, C Marguerie, K Davies, C Ross, **C Craddock**, Churchill Livingstone.

GRANTS:

Co-applicant with Prof B Turner and Dr C Bunce on grant entitled “Histone deacetylases as therapeutic targets in acute myeloid leukaemia”. Funded by Leukaemia Research Fund 2002-2004 (£110,000).

Co-applicant with Prof M Wakelam on grant entitled “Use of proteomics to characterise abnormalities in receptor tyrosine kinase signalling in patients with acute myeloid leukaemia” Funded by Research Grants Committee Special Trustees of University Hospital NHS Trust 2002-2006 (£59,000).

Co-applicant with Professor P Moss (P.I.) and 14 others on NTRAC award to Institute of Cancer Studies Gene and Immunotherapy Award 2002-2007 (£ 2,000,000).

Co-applicant with Prof J Hartley and Dr D Hochhauser on grant entitled “Repair of DNA Interstrand Crosslinks as a Mechanism of Clinical Resistance to Melphalan in Multiple Myeloma.” Funded by Leukaemia Research Fund 2003-2006 (£140,000).

Principal Investigator on grant entitled “Phase II study of the tolerability and efficacy of the histone deacetylase inhibitor sodium valproate given in conjunction with ATRA (all trans retinoic acid) in patients with acute myeloid leukaemia”. Funded by the Leukaemia Research Fund 2004-2007 £217,000.

Co-applicant with Prof BM Turner “Phase II Study Of The Tolerability And Efficacy Of The Histone Deacetylase Inhibitor Sodium Valproate Given In Conjunction With ATRA in Patients With Acute Myeloid Leukaemia” Leukaemia and Lymphoma Research 2004-2007 £180,000.

Principal applicant Early phase clinical trial development award: Regional Research Network, Cure Leukaemia, £600,000 2007-2011.

Co-applicant with Prof P Moss on programme grant entitled ”Studies to potentiate the graft-versus-leukaemia effect of stem cell transplantation” Funded by Leukaemia Research Fund 2004-2009 (£1,000,000).

Principal investigator on grant entitled “Phase II study of the tolerability and efficacy of the histone deacetylase inhibitor sodium valproate given in conjunction with 5-azacitidine, theophylline and ATRA in patients with AML and high-risk MDS”. Funded by the Leukaemia Research Fund. 2005-2007.

Principal applicant £2.2 million capital grant from Advantage West Midlands for establishment of Center for Clinical Haematology, University Hospital Birmingham NHS Foundation Trust.

Co-investigator with Dr T Stankovic “Mechanism of action of histone deacetylase inhibitors” £320,000 Kay Kendall Fund 2006-2009.

Co-applicant with Professor P Johnson “Establishment of a National Phase II Trial unit in Haematological Malignancies” £280,000 Leukaemia Research 2007-2010.

Co-applicant with Professor P Moss “Investigations into a graft-versus-leukaemia effect after allogeneic stem cell transplantation” £800,000 Leukaemia research 2007-2012.

Co-applicant with Professor P Moss “An Investigation into T Cell Function of Patients Receiving Tyrosine Kinase Inhibitors”£180,000 2009-2012.

Co-applicant with Professor P Moss "Study of Mechanisms Underlying the Graft Versus Leukaemia Effect in Stem Cell Transplantation." Awarded £809,498.00 for 3 years Leukaemia and Lymphoma Research Start 2010.

Principal Applicant “Establishment of a Therapy Acceleration Programme” £1.7 million Leukaemia and Lymphoma Research 2011-2014.

Principal Applicant “A phase I trial of combined azacitidine and lenalidomide salvage therapy in patients with acute myeloid leukaemia who relapse after allogeneic stem cell transplantation” Leukaemia and Lymphoma Research 2013 – 2016.

Principal Applicant “Evaluating the role of minimal residual disease monitoring in predicting outcome after reduced intensity allografts in AML” £117,021.00 Leukaemia and Lymphoma Research 2013 – 2016.

Principal Applicant “A Randomised Trial of the FLAMSA-BU Conditioning Regimen in patients with acute myeloid leukaemia and myelodysplasia undergoing allogeneic stem cell transplantation – FIGARO” £180,392.00 Leukaemia and Lymphoma Research 2013-2018.

Co-applicant with Professor M Overduin “Structure based drug discovery for a juvenile myelomonocytic leukaemia target” £490,929.00.

Principal Applicant “Characterisation of the immune sequelae of post-transplant azacitidine and lenalidomide in patients with relapsed AML” £75,985.00 Leukaemia and Lymphomas Research 2014-2016.

Lead Applicant “Establishment of a Birmingham Institute of Translational Medicine” on behalf of Birmingham Health Partners as a component of the Birmingham City Deal submitted by Greater Birmingham and Solihull LEP £12 million 2012-2015.

Co-applicant with Dr R Malladi “A Phase II study of the use of Azacitidine for the treatment of patients with chronic graft-versus-host disease who have failed therapy with corticosteroids (AZTEC)” £174,134.00 Leukaemia and Lymphoma Research 2014-2018.

Principal Applicant “Renewal of a Therapy Acceleration Programme” £5.3 million Leukaemia and Lymphoma Research 2015-2020.

Co-applicant with Dr C Yap and Prof L J Billingham “Improving the power of phase II oncology trials through the use of continuous tumour measurements” £11,792. University of Birmingham-CCTU 2015.

Lead Applicant “Establishment of a Birmingham Centre for Clinical Haematology” GBSLEP Local Growth Fund £2.42 million 2017.

Lead Applicant “Establishment of a UK Transplant Trials Network: IMPACT The UK’s Stem Cell Transplant Clinical Trials Platform £3.4 million Anthony Nolan, Leuka, NHSBT 01/01/2017-31/12/2020.

Co-Applicant “A Phase 2a trial of Avelumab, an anti-PDL 1 antibody in relapsed and refractory peripheral T-cell lymphoma (AVAIL-T)”, £281,567 Pfizer Limited 06/07/2017-05/06/2022

Co-Applicant Cancer Research Clinical Trials Unit, Adult Unit £1,071,790 Cancer Research UK 01/10/2018-30/09/2023

Co-Applicant Cancer Research Clinical Trials Unit, Paediatric Unit £1,106,854 Cancer Research UK 01/10/2018-30/09/2023

Lead Applicant “AMADEUS – Double-blind, IMPACT, phase III. Randomised Study to Compare the Efficiency and Safety to Oral AZA(CC-486) Versus Placebo in Subject with Acute Myeloid Leukaemia or Myelodysplastic Syndromes as Maintenance after Allogeneic Haematopoietic” £6,678,806, Celgene International II Sarl 01/04/2018 – 31/03/2025

Co-Applicant “STELLAR: A Phase 2, Randomised Study of CHOP-R in Combination with acalabrutinib at disease progression for patients...” £951,530, Acerta Pharma B V, 07/12/2018 – 06/12/2025.

Co-Applicant “Promise: Investigation into the combination of a Plexxikon BETi with ruxolitinib in patients with high or intermediate-2 risk myelofibrosis not receiving and an adequate response with ruxolitinib alone (Adam Mead)” £23,586, Cancer Research UK, 01/05/2019 – 30/04/2023.

PROFESSIONAL ORGANISATIONS:

2019- present	Chair NCRI AML Working Party
2018-present	Chief Medical and Scientific Advisor Anthony Nolan
2017 – present	Hub Lead IMPACT Transplant Trial Network
2017-present	Medical Director Cure Leukaemia
2015 – present	Vice Chair (Europe) Center for International Blood and Marrow Transplant Research

2015 – present	Chair European Bone Marrow Transplant Group Clinical Trials Committee
2014 – 2017	Member of American Society Hematology Publications Committee
2014 – present	Chair Anthony Nolan Scientific Advisory Committee
2012 – 2019	Board Member Birmingham Health Partners
2012 – 2013	Translational Director Birmingham Health Partners
2011 – present	Director UK Haemato-oncology Trials Acceleration Programme
2010 – 2014	Medical Director – Anthony Nolan
2010 – present	Chair UK Stem Cell Oversight Committee
2010 – 2012	Member International Scientific Advisory Board (SAB) of the Erasmus Stem Cell Institute (ESI)
2006 – present	Member Education Committee European Haematology Association
2006 – 2009	Member of NCRN Haemato-oncology Study Group
2005 – 2007	President of British Society for Bone Marrow Transplantation
2005 – 2010	Member of NCRN Chronic Myeloid Leukaemia Working Party
2004 – 2011	Member Leukaemia Research Fund Clinical Trials Advisory Panel
2004 – 2009	Member of Adult Leukaemia Working Party
2004 – present	Director of the Centre for Clinical Haematology, Birmingham
2003- present	Founding Member and Trustee Cure Leukaemia
2002 – present	Directors Committee University of Birmingham CRUK Clinical Trials Unit

EDITORIAL RESPONSIBILITIES:

2018 – present

Associate Editor – Journal of Clinical Oncology

2016-2018

Editorial Board – Journal of Clinical Oncology

Regular Reviewer: New England Journal of Medicine, Blood, Leukaemia, Lancet Haematology, Lancet Oncology, Biology of Blood and Marrow Transplant, Leukaemia, Bone Marrow Transplantation